Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -1948.43% is 88% above its 5-year average of -15599.82%, near the low end of its 5-year range (-87996.64%–9082100.00%).
85.21% above its 12-month average of -13169.61%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): -25702.86%.
EBITDA MARGIN
-1948.43%
EBITDA MARGIN AVG TTM
-13169.61%
EBITDA MARGIN AVG 3Y
1119041.18%
EBITDA MARGIN AVG 5Y
-15599.82%
EBITDA MARGIN AVG 10Y
N/A
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+85.21%
CURRENT VS 3Y AVG
-100.17%
CURRENT VS 5Y AVG
+87.51%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Relay Therapeutics, Inc.
Market Cap
$4.09B
EBITDA Margin
-1948.43%
TTM Avg
-13169.61%
3Y Avg
1119041.18%
5Y Avg
-15599.82%
Market Cap
$4.02B
EBITDA Margin
-250.61%
TTM Avg
-502.94%
3Y Avg
-374.26%
5Y Avg
-228.13%
Market Cap
$4.31B
EBITDA Margin
-14.19%
TTM Avg
-47.13%
3Y Avg
-77.82%
5Y Avg
-97.39%
Market Cap
$4.39B
EBITDA Margin
-31.52%
TTM Avg
-36.86%
3Y Avg
-49.55%
5Y Avg
-49.55%
Market Cap
$4.46B
EBITDA Margin
23.00%
TTM Avg
14.06%
3Y Avg
2.00%
5Y Avg
2.94%
Market Cap
$3.68B
EBITDA Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Relay Therapeutics, Inc. (RLAY) | $4.09B | -1948.43% | -13169.61% | 1119041.18% | -15599.82% |
| LivaNova PLC (LIVN)vs › | $4.12B | 17.39% | 15.89% | 7.31% | 2.27% |
| AbCellera Biologics Inc. (ABCL)vs › | $4.02B | -250.61% | -502.94% | -374.26% | -228.13% |
| ICU Medical, Inc. (ICUI)vs › | $4.00B | 14.57% | 8.24% | 9.01% | 11.36% |
| Edgewise Therapeutics, Inc. (EWTX)vs › | $4.31B | N/A | N/A | N/A | N/A |
| Adaptive Biotechnologies Corporation (ADPT)vs › | $4.31B | -14.19% | -47.13% | -77.82% | -97.39% |
| Heartflow, Inc. Common Stock (HTFL)vs › | $4.39B | -31.52% | -36.86% | -49.55% | -49.55% |
| Indivior Pharmaceuticals Inc (INDV)vs › | $4.46B | 23.00% | 14.06% | 2.00% | 2.94% |
| Regencell Bioscience Holdings Limited (RGC)vs › | $3.68B | N/A | N/A | N/A | N/A |
| BillionToOne, Inc. (BLLN)vs › | $4.60B | 9.15% | -7.04% | -33.99% | -33.99% |
Gross Margin
76.8%
EBITDA Margin
-1948.4%
Operating Margin
-1971.6%
Net Margin
-2763.6%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | -25702.86% |
| 2026-03-31 | -2602.87% |
| 2025-06-30 | -11203.10% |
| 2025-03-31 | -1089.48% |
| 2024-03-31 | -889.06% |
| 2023-12-31 | 9082100.00% |
| 2023-09-30 | -286.54% |
| 2023-06-30 | -87996.64% |
| 2023-03-31 | -44238.94% |
| 2022-12-31 | -28333.99% |
| 2022-09-30 | -24668.31% |
| 2022-06-30 | -21056.16% |
| 2022-03-31 | -14736.52% |
| 2021-12-31 | -11761.73% |
| 2021-09-30 | -9005.71% |
| 2021-06-30 | -22822.27% |
| 2021-03-31 | -4357.77% |
| 2020-12-31 | 43.43% |
